Published today in @JCOPO_ASCO 🧬
In 3,274 Lynch syndrome carriers, 144 patients developed 224 urothelial cancers. MSH2/EPCAM was strongly associated with UC risk (HR 4.43), and UC was the first malignancy in 34.7%.
Toward genotype-adapted surveillance. ascopubs.org/doi/10.1200/PO-…
Robert Hüneburg retweeted
CADLY2: ADR 34% with AI-assisted colonoscopy vs 31% with HD white light in Lynch surveillance, not significant. CADe may add little at expert centers.
Read our breakdown of the Lancet study: ow.ly/Ul5950ZAZZg
@RHuneburg @LancetGastroHep
Our international CADLY2 trial is now published in @LancetGastroHep.
In 757 people with Lynch syndrome, AI-assisted colonoscopy did not significantly improve adenoma detection in expert surveillance centres.
Grateful to all participants and investigators.
Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…
Since last year, we have established mandatory tumor-based testing for signs of Lynch syndrome in all colorectal cancers treated at DKG-certified centers. This turns risk into structured prevention for families — and is now recognized with the Felix Burda Award 2026.
📌In this multicenter Lynch syndrome cohort, 21% developed metachronous CRC despite surveillance recommendations—highlighting high long-term risk and limited adherence, and supporting personalized surgical and follow-up strategies. @RHUNEBURG
🔗: ow.ly/ko3r50YvMSQ
Robert Hüneburg retweeted
As 2025 comes to a close, we send a heartfelt thank you to our members and the wider #HereditaryGICancer community for your continued support of CGA-IGC 💙
We’re grateful for your engagement and look forward to connecting and collaborating with you in the year ahead
Robert Hüneburg retweeted
📢Join us next week for our final Hereditary Live session of 2025! 🧬
🚨Add Thursday’s session to your calendar and receive the link to join👇
evt.to/Ci24303019
➡️We’ve got a fantastic lineup of cases, 3 from the 🇺🇸 and 1 from 🇩🇪 all offering an incredible learning opportunity for the entire multidisciplinary #HereditaryGICancer care team
➡️Whether you’re seasoned in this field or just starting out, Hereditary Live is a 👍way to learn from 🌍top experts through real-world case discussions💡
📍Huge thanks to the @ClevelandClinic, our moderators, case presenters & everyone who shared their time & expertise throughout 2025 🙏
You’ve helped make this series an invaluable resource for our members and the wider community!
🎧 New podcast episode with Alexander Meining on endoscopic management in FAP:
– Surveillance after colectomy
– Polypectomy protocols for upper GI lesions
– Open questions in clinical practice
🎙️ Listen now:
#FAP #Endoscopy #Gastroenterology
open.spotify.com/episode/7tV…
Thanks for highlighting our study!
🧬 multicenter cohort of 852 LS carriers with prior CRC, we identified
• Male sex (HR 2.16)
• Older age at first CRC (HR 1.03 per year)
• Left-sided primary CRC (HR 1.53)
as independent risk factors for metachronous CRC
Identifying risk factors for metachronous colorectal cancer in Lynch syndrome
@AGA_CGH
doi.org/10.1016/j.cgh.2025.0…
👉852 LS carriers, 21.1% metachronous CRC
👉RF: Male sex, older age, left-sided tumor & partial colectomy
🧐supports personalized counseling
@myESMO
Robert Hüneburg retweeted
Identifying risk factors for metachronous colorectal cancer in Lynch syndrome
@AGA_CGH
doi.org/10.1016/j.cgh.2025.0…
👉852 LS carriers, 21.1% metachronous CRC
👉RF: Male sex, older age, left-sided tumor & partial colectomy
🧐supports personalized counseling
@myESMO
Robert Hüneburg retweeted
🚨 Our study: Largest International cohort of CDH1 pathogenic variant carriers 👫 we found ⬆️ adenoma detection rate (up to 48.6%) and early-onset CRC cases 🦀—even before age 50.
This suggests ❓ need for earlier colorectal screening in this population.
📖 bit.ly/CDH1COLON
@CCF_GIFellows #CarolBurke @RHuneburg @LadyKatherineM1 @JPAchkarMD @DavidLiskaMD @familialcancer
Finally out.... great cooperation with Carol Burke, @Chatterjee_MD
and Cleveland Clinic assistance well as our German Consortium.
Colonoscopy findings in CDH1 carriers from a multicenter international study. pubmed.ncbi.nlm.nih.gov/4032…
Finally out.... great cooperation with Carol Burke, @Chatterjee_MD
and Cleveland Clinic assistance well as our German Consortium.
Colonoscopy findings in CDH1 carriers from a multicenter international study. pubmed.ncbi.nlm.nih.gov/4032…
New in @NatureComms:
IL-17A⁺NKp44(–) ILC3s accumulate in FAP duodenal tissue and may drive tumorigenesis via ROS-mediated DNA damage by our group.
nature.com/articles/s41467-0…
Robert Hüneburg retweeted
📢#LynchSyndromeAwarenessDay may be over but the education continues
➡️Join our colleagues & friends from @DanaFarber & the wider #HereditaryGICancer community for this FREE #LynchSyndrome Scientific Symposium
🗓️Wed April 16
⌚️9am-5pm
✍️redcap.link/LynchSymposium20…
📍An impressive program with expert speakers, many of them #CGAIGC members➕Sir John Burn (@CaPP3) & @RHuneburg
@asaf_maoz @EdEsplin @MattYurgelun @MSpringerGC @AlexMannucci @pAla2Arg @josiebakerGC @Alive_And_Kickn
There’s still time to join us for our @DanaFarber #LynchSyndrome Scientific Symposium all day Wed April 16.
Available virtually or in-person for FREE!
Register at: redcap.link/LynchSymposium20…
Robert Hüneburg retweeted
There’s still time to join us for our @DanaFarber #LynchSyndrome Scientific Symposium all day Wed April 16.
Available virtually or in-person for FREE!
Register at: redcap.link/LynchSymposium20…
Robert Hüneburg retweeted
What fabulous news on the last day of #ColorectalCancerAwarenessMonth!
Congratulations @RHuneburg et al for this achievement. I know you will reach your target of 764 patients!
We eagerly await the results of this important study!
#HereditaryGICancer #LynchSyndrome
🚀 Patients 600, 601, and 602 enrolled! Today, we reached a new milestone in the CADLY2 trial, the largest randomized study to date comparing ADR in Lynch syndrome patients with and without the assistance of AI (CADe). @CGAIGC
@EHTGtweets cadly2.org
#CADLY2 #Lynch
🚀 Patients 600, 601, and 602 enrolled! Today, we reached a new milestone in the CADLY2 trial, the largest randomized study to date comparing ADR in Lynch syndrome patients with and without the assistance of AI (CADe). @CGAIGC
@EHTGtweets cadly2.org
#CADLY2 #Lynch
Robert Hüneburg retweeted
Presenting a digital tool to detect & count adenomas in #FAP patients during colonoscopy. Using real-time eye-tracking & voice recognition for data annotation. @Uni_WUE #UKB @Joeltroyasebas @RHuneburg Thanks to @SanderStiftung for the funding!



















